rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Revvity, Inc.

RVTY · NYSE

Health CareLife-science toolsLeading

RVTY stood above a rising 150-day average in 36 of the last 52 weekly readings, including each of the last 22 weeks. It is 36.9% above that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
22 in a row
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$11.9M
Officials’ trades on record
20
Institutions holding
505 (+40)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 36 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$9.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

20 disclosed lines: House 18, Senate 0, executive 2; 6 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$15k–$50k9 Sep 2026filed 12 Oct 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k4 Sep 2026filed 12 Oct 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31sold$1k–$15k3 Sep 2026filed 12 Oct 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$15k–$50k4 May 2026filed 8 Jun 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k1 May 2026filed 8 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k27 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$50k–$100k18 Mar 2026filed 14 May 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k12 Sep 2025filed 10 Oct 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k13 Aug 2025filed 12 Sep 2025
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k23 Jul 2025filed 14 Aug 2025
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k22 Jul 2025filed 13 Aug 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k17 Jun 2025filed 13 Aug 2025

Insiders

Buy orders, 12 months0
Sale orders, 12 months10
Buyers · sellers0 · 7
WhoDidSharesTraded
Anita GonzalesVP and CAOsold84at $155.481 Oct 2026filed 2 Oct 2026
Maxwell KrakowiakPlease See Remarkssold1,631at $144.5321 Sep 2026filed 23 Sep 2026
Tajinder S. VohraPlease See Remarkssold7,330at $140.8816 Sep 2026filed 18 Sep 2026
Anita GonzalesVice President and CAOsold85at $109.4820 Jul 2026filed 22 Jul 2026
Anita GonzalesVice President and CAOsold80at $92.8020 Apr 2026filed 22 Apr 2026
Miriame VictorPlease See Remarkssold1,862at $97.1324 Feb 2026filed 26 Feb 2026
Michelle McMurry-HeathDirectorsold600at $97.2623 Feb 2026filed 25 Feb 2026
Joel S. GoldbergPlease See Remarkssold6,424at $99.475 Feb 2026filed 6 Feb 2026
Joel S. GoldbergPlease See Remarkssold3,544at $100.505 Feb 2026filed 6 Feb 2026
Joel S. GoldbergPlease See Remarkssold2,217at $101.335 Feb 2026filed 6 Feb 2026
Joel S. GoldbergPlease See Remarkssold532at $102.525 Feb 2026filed 6 Feb 2026
Prahlad R. SinghPlease See Remarkssold1,307at $99.025 Feb 2026filed 6 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders505+40 on the quarter
New · exited99 · 59
Reported value$10.1B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20268,637,614$961.0M+8,637,614
EdgePoint Investment Group Inc.reduced · filed 14 Aug 20268,544,479$950.7M-256,384−2.9%
BlackRock, Inc.added · filed 7 Aug 20267,658,369$852.1M+407,993+5.6%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20267,300,973$812.3M-29,007−0.4%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 20264,770,448$530.8M-42,719−0.9%
STATE STREET CORPadded · filed 7 Aug 20264,342,739$483.2M+32,426+0.8%
VICTORY CAPITAL MANAGEMENT INCadded · filed 7 Aug 20263,645,905$405.6M+273,278+8.1%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20263,428,692$381.5M+510,739+17.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20262,955,227$328.2M+18,105+0.6%
MORGAN STANLEYreduced · filed 13 Aug 20262,574,826$286.5M-108,200−4.0%
31 Mar 2023 – 30 Jun 2026
421462502Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Anita Gonzales Company insiderVP and CAO · last 1 Oct 20260 · 3
Maxwell Krakowiak Company insiderPlease See Remarks · last 21 Sep 20260 · 2
Tajinder S. Vohra Company insiderPlease See Remarks · last 16 Sep 20260 · 11
Gilbert Ray Cisneros, Jr. HouseCA31 · last 9 Sep 20267 · 3
Alexis P. Michas Company insiderDirector · last 25 Aug 20262 · 25
Joel S. Goldberg Company insiderPlease See Remarks · last 14 Aug 20260 · 19
Prahlad R. Singh Company insiderPlease See Remarks · last 13 Aug 20260 · 8
Frank Witney Company insiderDirector · last 7 May 20260 · 0
Michael A. Klobuchar Company insiderDirector · last 7 May 20260 · 0
Michel Vounatsos Company insiderDirector · last 7 May 20260 · 0
Michelle McMurry-Heath Company insiderDirector · last 7 May 20260 · 3
Pascale Witz Company insiderDirector · last 7 May 20260 · 2

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

Awards19
Total$12.4M
Latest30 Sep 2026
2021$231K
2022$139K
2023$285K
2024$9.3M
2025$284K
2026$2.1M

From its SEC filings

Operating profit marginFY 2025 · to 28 Dec 202512.5%
Free cash flow marginFY 2025 · to 28 Dec 202517.8%
Return on capital employedFY 2025 · to 28 Dec 20253.3%
Cash conversionFY 2025 · to 28 Dec 2025242%
Debt to equityFY 2025 · to 28 Dec 20250.44×
Research spendFY 2025 · to 28 Dec 20257.6%
Dividend growthFY 2025 · to 28 Dec 2025300%
Share count trendFY 2025 · to 20 Feb 2026-0.4%
Cash and equivalentsFY 2025 · to 28 Dec 2025$919.9M
Free cash flowFY 2025 · to 28 Dec 2025$509.4M

Analyst forecasts

No analyst forecasts yet.